Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

United Therapeutics (UTHR) EBIAT (2016 - 2026)

United Therapeutics' EBIAT history spans 17 years, with the latest figure at $364.3 million for Q4 2025.

  • On a quarterly basis, EBIAT rose 20.91% to $364.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 11.68% increase, with the full-year FY2025 number at $1.3 billion, up 11.68% from a year prior.
  • EBIAT hit $364.3 million in Q4 2025 for United Therapeutics, up from $338.7 million in the prior quarter.
  • Over the last five years, EBIAT for UTHR hit a ceiling of $364.3 million in Q4 2025 and a floor of $28.3 million in Q1 2021.
  • Historically, EBIAT has averaged $235.9 million across 5 years, with a median of $250.0 million in 2023.
  • Biggest five-year swings in EBIAT: plummeted 79.45% in 2021 and later surged 747.7% in 2022.
  • Tracing UTHR's EBIAT over 5 years: stood at $112.2 million in 2021, then increased by 17.74% to $132.1 million in 2022, then skyrocketed by 64.35% to $217.1 million in 2023, then skyrocketed by 38.78% to $301.3 million in 2024, then grew by 20.91% to $364.3 million in 2025.
  • Business Quant data shows EBIAT for UTHR at $364.3 million in Q4 2025, $338.7 million in Q3 2025, and $309.5 million in Q2 2025.